DK2632446T3 - Behandling af dupuytrens kontraktur - Google Patents
Behandling af dupuytrens kontraktur Download PDFInfo
- Publication number
- DK2632446T3 DK2632446T3 DK11779628.4T DK11779628T DK2632446T3 DK 2632446 T3 DK2632446 T3 DK 2632446T3 DK 11779628 T DK11779628 T DK 11779628T DK 2632446 T3 DK2632446 T3 DK 2632446T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- tnf
- composition
- dupuytren
- antagonist
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 118
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 110
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 101
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 100
- 239000005557 antagonist Substances 0.000 claims description 88
- 201000010099 disease Diseases 0.000 claims description 79
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 59
- 102000029816 Collagenase Human genes 0.000 claims description 55
- 108060005980 Collagenase Proteins 0.000 claims description 55
- 229960002424 collagenase Drugs 0.000 claims description 53
- 210000002744 extracellular matrix Anatomy 0.000 claims description 40
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 39
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 39
- 210000001519 tissue Anatomy 0.000 claims description 33
- 230000000893 fibroproliferative effect Effects 0.000 claims description 31
- 208000006111 contracture Diseases 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 230000015556 catabolic process Effects 0.000 claims description 27
- 238000006731 degradation reaction Methods 0.000 claims description 27
- 238000003776 cleavage reaction Methods 0.000 claims description 26
- 230000007017 scission Effects 0.000 claims description 26
- 206010062575 Muscle contracture Diseases 0.000 claims description 24
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 23
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 23
- 206010016629 fibroma Diseases 0.000 claims description 12
- 206010049444 fibromatosis Diseases 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 229960000598 infliximab Drugs 0.000 claims description 7
- 208000004362 Penile Induration Diseases 0.000 claims description 6
- 208000020758 Peyronie disease Diseases 0.000 claims description 6
- 229960003115 certolizumab pegol Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000009975 plantar fibromatosis Diseases 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 208000016272 Ledderhose disease Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 229960002964 adalimumab Drugs 0.000 claims description 4
- 229960000403 etanercept Drugs 0.000 claims description 4
- 229960001743 golimumab Drugs 0.000 claims description 4
- 201000003687 Plantar fascial fibromatosis Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 208000023835 Tendon disease Diseases 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000002962 histologic effect Effects 0.000 claims 1
- 208000013515 tendinosis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 84
- 210000000651 myofibroblast Anatomy 0.000 description 63
- 210000002950 fibroblast Anatomy 0.000 description 45
- 230000000694 effects Effects 0.000 description 31
- 208000035475 disorder Diseases 0.000 description 30
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 24
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 24
- 230000008602 contraction Effects 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 20
- 230000002500 effect on skin Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 16
- 210000001503 joint Anatomy 0.000 description 15
- 210000001616 monocyte Anatomy 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 239000000512 collagen gel Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 206010034464 Periarthritis Diseases 0.000 description 10
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000013610 patient sample Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 9
- 108700010013 HMGB1 Proteins 0.000 description 9
- 101150021904 HMGB1 gene Proteins 0.000 description 9
- 102100037907 High mobility group protein B1 Human genes 0.000 description 9
- 102100032442 Protein S100-A8 Human genes 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010061818 Disease progression Diseases 0.000 description 7
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000005750 disease progression Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000003518 stress fiber Anatomy 0.000 description 6
- 230000006433 tumor necrosis factor production Effects 0.000 description 6
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 5
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 102100025136 Macrosialin Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 108010009711 Phalloidine Proteins 0.000 description 5
- 102000001400 Tryptase Human genes 0.000 description 5
- 108060005989 Tryptase Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011477 surgical intervention Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108010028275 Leukocyte Elastase Proteins 0.000 description 4
- 102000016799 Leukocyte elastase Human genes 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003195 fascia Anatomy 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010061819 Disease recurrence Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 3
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 3
- 102100032420 Protein S100-A9 Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 206010023201 Joint contracture Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 201000010603 frozen shoulder Diseases 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000026447 protein localization Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- -1 mast cells Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000030346 palmar fibromatosis Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000019539 pyogenic bacterial infections due to MyD88 deficiency Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007769 storiform growth pattern Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Sammensætning til anvendelse til behandling af et tidligt stadie af muskuloskele-tal fibroproliferativ lidelse, hvor sammensætningen omfatter en terapeutisk, profylaktisk eller progressionsinhiberende effektiv mængde af en TNF-a-antagonist, hvor sygdommen er kendetegnet ved tilstedeværelsen af tegn eller symptomer på sygdom, men hvor der ikke optræder betydelig kontraktur.
2. Sammensætning ifølge krav 1 til anvendelse ifølge krav 1, hvor tegnene eller symptomerne på sygdom er tilstedeværelsen af histologiske knuder og/eller tilstedeværelsen af kliniske knuder.
3. Sammensætning ifølge krav 1 eller krav 2 til anvendelse ifølge krav 1 eller 2, hvor den muskuloskeletale fibroproliferative lidelse er fibromatosesygdom.
4. Sammensætning ifølge et hvilket som helst af kravene 1 til 3 til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor den muskuloskeletale fibroproliferative lidelse er valgt blandt Dupuytrens kontraktur, Ledderhoses sygdom, Peyronies sygdom og muskuloskeletale adhæsioner.
5. Sammensætning ifølge krav 4, til anvendelse ifølge krav 4, hvor de muskuloskeletale adhæsioner er valgt blandt adhæsiv kapsulit og tendinose.
6. Sammensætning ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den muskuloskeletale fibroproliferative lidelse er Dupuytrens kontraktur.
7. Sammensætning ifølge krav 6 til anvendelse ifølge krav 6, hvor forstyrrelsen er kendetegnet ved kontraktur i led på mindre end 20°.
8. Sammensætning ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, som er til lokal anvendelse på områder, hvor sygdommen manifesterer sig eller giver symptomer.
9. Sammensætning ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, som omfatter en TNF-a-antagonist og et middel til nedbrydning, indskrænkelse eller kløvning af ekstracellulær matrix.
10. Sammensætning ifølge krav 9 til anvendelse ifølge krav 9, hvor midlet til nedbrydning, indskrænkelse eller kløvning af ekstracellulær matrix er en matrix-metalloproteinase og/eller en kollagenase.
11. Sammensætning ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, hvor sammensætning er formuleret til direkte injektion i sygt væv.
12. Sammensætning ifølge krav 11 til anvendelse ifølge krav 11, hvor sammensætning er til direkte injektion i knuder.
13. Sammensætning ifølge et hvilket som helst af kravene 1 til 10 til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor sammensætningen er formuleret til topisk påføring.
14. Sammensætning ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, hvor TNF-a-antagonisten er valgt blandt en eller flere af Infliximab, Adalimumab, Certolizumab pegol, Golimumab eller Etanercept.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1018325.9A GB201018325D0 (en) | 2010-10-30 | 2010-10-30 | Treatment for dupuytren's disease |
| GBGB1018362.2A GB201018362D0 (en) | 2010-11-01 | 2010-11-01 | Treatment of dupuytren's disease |
| GBGB1113718.9A GB201113718D0 (en) | 2011-08-10 | 2011-08-10 | Treatment of Dupuytren's Disease |
| PCT/EP2011/069147 WO2012056044A1 (en) | 2010-10-30 | 2011-10-31 | Treatment for dupuytren's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2632446T3 true DK2632446T3 (da) | 2019-04-01 |
Family
ID=44913268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11779628.4T DK2632446T3 (da) | 2010-10-30 | 2011-10-31 | Behandling af dupuytrens kontraktur |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9138458B2 (da) |
| EP (1) | EP2632446B1 (da) |
| JP (2) | JP6004494B2 (da) |
| AU (2) | AU2011322482B2 (da) |
| CA (1) | CA2847197C (da) |
| DK (1) | DK2632446T3 (da) |
| ES (1) | ES2715204T3 (da) |
| RU (1) | RU2013123796A (da) |
| WO (1) | WO2012056044A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2632446B1 (en) | 2010-10-30 | 2018-12-12 | Oxford University Innovation Limited | Treatment for dupuytren's disease |
| JP2015521169A (ja) | 2012-05-01 | 2015-07-27 | プロテオリース リミテッド | 抜歯する方法 |
| US20130297023A1 (en) * | 2012-05-07 | 2013-11-07 | Hee-Jeong Im Sampen | Methods and Devices For Treating Intervertebral Disc Disease |
| WO2015006469A2 (en) * | 2013-07-11 | 2015-01-15 | 180 Therapeutics Lp | Method of treating fibroproliferative disorders including dupuytren ' s disease with one or more specific human matrix metalloproteinase and a tnf antagonist |
| EP3265493B1 (en) | 2015-03-02 | 2024-01-10 | 180 Therapeutics LP | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| EP4215210A1 (en) * | 2016-04-08 | 2023-07-26 | 180 Therapeutics LP | Method of treating early stage dupuytren's disease |
| US20190225682A1 (en) * | 2016-09-02 | 2019-07-25 | 180 Therapeutics Lp | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
| EP3506920A4 (en) * | 2016-09-02 | 2020-05-27 | 180 Therapeutics LP | METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY |
| US11564963B2 (en) | 2017-11-22 | 2023-01-31 | Progeneron, Llc | Topical compositions, process of large-scale manufacture, and method of use |
| EP3980022B1 (en) | 2019-06-07 | 2025-01-15 | Dale Biotech, LLC | Treatment of dupuytren's disease, osteoarthritis, or adhesive capsulitis with rhamnolipids. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10399023I2 (de) * | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
| US6486140B2 (en) * | 1994-07-19 | 2002-11-26 | Medicarb Ab | Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CN1083337C (zh) | 1996-03-26 | 2002-04-24 | 精工爱普生株式会社 | 打印装置及其控制方法 |
| US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| US6031005A (en) * | 1998-08-03 | 2000-02-29 | Easterling; W. Jerry | Composition and method for treating Peyronie's disease and related connective tissue disorders |
| US6060474A (en) * | 1998-11-05 | 2000-05-09 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method for preventing scar tissue formation |
| GB0105330D0 (en) | 2001-03-02 | 2001-04-18 | Renovo Ltd | Genetic testing |
| ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| JP2004532230A (ja) * | 2001-04-30 | 2004-10-21 | アラクノーバ・セラピューティックス・リミテッド | Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置 |
| ATE427758T1 (de) | 2002-07-05 | 2009-04-15 | Univ Laval | Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen |
| GB0306165D0 (en) | 2003-03-18 | 2003-04-23 | Delta G Ltd | Medical treatment |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| AU2005210668A1 (en) * | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
| PL1846022T3 (pl) * | 2005-01-21 | 2016-06-30 | Univ New York State Res Found | Sposoby leczenia zarostowego zapalenia torebki stawowej |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| JP5649589B2 (ja) | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用 |
| CA2757768A1 (en) | 2009-03-06 | 2010-09-10 | Kenneth William Gregg | Bacterial composition for eliciting sustained feeding behavior in fish |
| EP2632446B1 (en) | 2010-10-30 | 2018-12-12 | Oxford University Innovation Limited | Treatment for dupuytren's disease |
-
2011
- 2011-10-31 EP EP11779628.4A patent/EP2632446B1/en active Active
- 2011-10-31 RU RU2013123796/15A patent/RU2013123796A/ru not_active Application Discontinuation
- 2011-10-31 JP JP2013535462A patent/JP6004494B2/ja active Active
- 2011-10-31 DK DK11779628.4T patent/DK2632446T3/da active
- 2011-10-31 US US13/882,262 patent/US9138458B2/en active Active
- 2011-10-31 ES ES11779628T patent/ES2715204T3/es active Active
- 2011-10-31 WO PCT/EP2011/069147 patent/WO2012056044A1/en not_active Ceased
- 2011-10-31 CA CA2847197A patent/CA2847197C/en active Active
- 2011-10-31 AU AU2011322482A patent/AU2011322482B2/en active Active
-
2015
- 2015-09-11 US US14/852,442 patent/US10273296B2/en active Active
-
2016
- 2016-08-29 JP JP2016166524A patent/JP2017014266A/ja active Pending
-
2017
- 2017-06-23 AU AU2017204267A patent/AU2017204267B2/en active Active
-
2019
- 2019-04-30 US US16/399,547 patent/US10669334B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2632446B1 (en) | 2018-12-12 |
| ES2715204T3 (es) | 2019-06-03 |
| CA2847197C (en) | 2020-11-03 |
| US20130287760A1 (en) | 2013-10-31 |
| US10669334B2 (en) | 2020-06-02 |
| US9138458B2 (en) | 2015-09-22 |
| US20190322733A1 (en) | 2019-10-24 |
| AU2017204267B2 (en) | 2019-05-23 |
| WO2012056044A1 (en) | 2012-05-03 |
| CA2847197A1 (en) | 2012-05-03 |
| US10273296B2 (en) | 2019-04-30 |
| AU2011322482A1 (en) | 2013-05-23 |
| EP2632446A1 (en) | 2013-09-04 |
| AU2017204267A1 (en) | 2017-07-13 |
| RU2013123796A (ru) | 2014-12-10 |
| JP2017014266A (ja) | 2017-01-19 |
| US20160280775A1 (en) | 2016-09-29 |
| AU2011322482B2 (en) | 2017-03-23 |
| JP6004494B2 (ja) | 2016-10-12 |
| JP2013540803A (ja) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10669334B2 (en) | Treatment for Dupuytren's disease | |
| JP4668902B2 (ja) | 創傷治癒を促進するための薬剤組成物及び方法 | |
| US10961321B1 (en) | Methods and compositions for treating pain associated with inflammation | |
| CN101146547A (zh) | 肌肉生长抑制素（gdf-8）拮抗剂用于增进创伤愈合和防止纤维变性疾病的用途 | |
| Huang et al. | Pharmacological treatment for keloids | |
| US11518801B1 (en) | Methods and compositions for treating diabetes and diabetic complications | |
| TW202033558A (zh) | 化膿性汗腺炎治療中使用的抗cd40抗體 | |
| US20240000930A1 (en) | Methods and compositions for treating kidney diseases | |
| Kragballe | Management of difficult to treat locations of psoriasis | |
| KR20190014454A (ko) | Crif1 억제제를 함유하는 켈로이드 및 비후성 반흔 형성 억제 또는 치료용 조성물 | |
| WO2024102157A1 (en) | Methods and compositions for treating diabetes and diabetic complications | |
| KR102206017B1 (ko) | Parp1 저해제를 포함하는 피부 섬유화 질환 치료용 약학적 조성물 | |
| WO2013064585A1 (en) | Treatment of musculoskeletal fibroproliferative disorders | |
| AU2017248273B2 (en) | Method of treating early stage Dupuytren's disease | |
| EP4267245B1 (en) | Anti-calnexin antibody for use in reducing cartilage degradation | |
| JP2016513968A (ja) | Ｏ−結合ｎ−アセチルグルコサミントランスフェラーゼを標的する組成物及び方法並びに創傷治癒を促進する組成物及び方法 | |
| Nanchahal et al. | Treatment for dupuytren's disease | |
| US12221463B2 (en) | Method of promoting wound healing by inhibiting CCR3 | |
| WO2014023952A2 (en) | Prevention and treatment of osteoarthritis | |
| US11980635B2 (en) | Methods of oral administration of protocatechuic acid for treating or reducing the severity of a joint injury or disease | |
| EP4308231A1 (en) | Wound healing enhancement with anti-ceramide antibodies | |
| Castellucci et al. | 43nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung eV (ADF) |